Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Guardant Health, Inc.
< Previous
1
2
3
4
5
Next >
Guardant Health to Participate in Upcoming Investor Conferences
August 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
August 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
August 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
August 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
August 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
July 29, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
July 24, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
July 23, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
July 18, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
June 04, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
June 03, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Named to TIME100 Most Influential Companies
May 31, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
May 30, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
May 23, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 23, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Participate in Upcoming Investor Conferences
May 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 21, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
May 09, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Participate in Upcoming Investor Conferences
May 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
May 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
April 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
April 18, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
April 03, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
March 13, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
March 01, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
February 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
Guardant Health to Participate in Upcoming Investor Conferences
February 15, 2024
From
Guardant Health, Inc.
Via
Business Wire
Tickers
GH
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.